PharmacoEconomics & Outcomes News 784, p35 - 12 Aug 2017 NICE: Roche invited to submit CDF proposal for atezolizumab NICE has asked Roche to submit a Cancer Drugs Fund (CDF) proposal for the immunotherapy drug, atezolizumab [Tecentriq], for advanced urothelial cancer. The invitation came after NICE’s earlier assessment found stronger evidence is needed to show the drug is both clinically and cost effective. Including the drug in the CDF means patients can access the treatment while the company gathers more data. Commenting on the draft appraisal, Director of the Centre for Health Technology Evaluation at NICE, Professor Carole Longson noted "there is a lack of new treatment options for people who have advanced urothelial cancer, so I am very disappointed we’ve not been able to recommend atezolizumab at this stage . . . I hope Roche will work with us to submit a CDF proposal. Funding through the CDF means it could be offered to patients who cannot undergo chemotherapy while we collect more evidence. This will be a positive step for a lot of people". NICE. Roche invited to submit a CDF proposal for urothelial cancer drug. Internet Document : 2 Aug 2017. Available from: URL: https://www.nice.org.uk/news/ article/roche-invited-to-submit-a-cdf-proposal-for-urothelial-cancer- drug 803263082 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784
PharmacoEconomics & Outcomes News – Springer Journals
Published: Aug 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera